SCHEMBL25429443

SCHEMBL25429443

O=C(O)c1ccc2c(c1)[nH]c(=O)n2-c1cccc(OC(F)F)c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 2/20 0.50
▸ MAT2A P31153 3/20 0.47
▸ MEN1 O00255 2/20 0.45
▸ LMNA P02545 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ KDM4E B2RXH2 2/20 0.43
▸ THRB P10828 1/20 0.42
▸ CSNK2A1 P68400 2/20 0.41
▸ MRGPRX4 Q96LA9 1/20 0.41
▸ DGAT2 Q96PD7 1/20 0.40
▸ PTGER1 P34995 1/20 0.40
▸ TOP2A P11388 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ GLA P06280 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ B3GNT2 Q9NY97 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29703089 1.00 AURKA (0.50) AURKAMAT2AMEN1LMNAKMT2A
SCHEMBL29703038 0.88 ALDH1A1 (0.47) MAT2AMEN1LMNAKMT2AL3MBTL1
SCHEMBL25351200 0.88 ALDH1A1 (0.47) MAT2AMEN1LMNAKMT2AL3MBTL1
SCHEMBL6840347 0.82 AURKA (0.64) AURKAMAT2AMEN1LMNAKMT2A
SCHEMBL25353354 0.79 DGAT2 (0.59) MEN1KMT2ADGAT2
SCHEMBL25353347 0.79 DGAT2 (0.68) MEN1KMT2ADGAT2
SCHEMBL29703173 0.79 DGAT2 (0.68) MEN1KMT2ADGAT2
SCHEMBL25432123 0.77 DGAT2 (0.65) KMT2ADGAT2
SCHEMBL25432125 0.77 DGAT2 (0.57) MEN1KMT2ADGAT2
SCHEMBL29703034 0.77 DGAT2 (0.65) KMT2ADGAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4225739-B1 PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-01-21 — — EP disclosed
US-11976061-B2 Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors Merck Sharp & Dohme, LLC (US) 2024-05-07 — — US disclosed
US-11976061-B2 Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors Merck Sharp & Dohme, LLC (US) 2024-05-07 — — US disclosed
US-11976061-B2 Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors Merck Sharp & Dohme, LLC (US) 2024-05-07 — — US disclosed
CN-116685577-A Preparation of benzimidazolone derivatives as novel diacylglycerol O-acyltransferase 2 inhibitors 默沙东有限责任公司 2023-09-01 — — CN disclosed
EP-4225739-A1 PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS Merck Sharp & Dohme LLC (US) 2023-08-16 — — EP disclosed
US-20220112182-A1 PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2022-04-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220112182-A1 PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS DGAT2, DGAT1, ACAT2 AURKA 1408/4885MAT2A 347/4885MEN1 3513/4885
US-11976061-B2 Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors DGAT2, DGAT1, ACAT2 AURKA 1408/4885MAT2A 347/4885MEN1 3513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback